Guidance on use and implementation of outcomes-based managed entry agreements for rare disease treatments

Deliverable 10.3 from Work Package 10 to provide guidance to support consistent HTA appraisal for orphan medicinal products.Presentation of mixed methods research and tools to support implementation ofoutcomes-based managed entry agreements for rare disease treatments.